Mylan launches first generic of asthma drug, Advair Diskusat 70% less price than the brand
- by Team ABLE - 14 Feb, 2019
NASDAQ-listed Mylan N.V. has announced the launch of the first FDA-approved therapeutically equivalent, substitutablegeneric of Advair Diskus, WixelaInhub(fluticasone propionate and salmeterol inhalation powder, USP), approved by the U.S. Food and Drug Administration (FDA) through the Abbreviated New Drug Application (ANDA) pathway.
WixelaInhub is indicated forcertain patients with asthma or chronic obstructive pulmonary disease (COPD).
All the three strengths of WixelaInhub will be offered at a wholesale acquisition cost, 70% less than ADVAIR DISKUS and 67% less than GSK's authorized generic version which launched onFeb. 8. The wholesale acquisition costs of WixelaInhub 100 mcg/50 mcg, 250 mcg/50 mcg and 500 mcg/50 mcg strengthsare said to be $93.71,$116.44and$153.14, respectively.
Commenting on this launch, Mylan's Chief Commercial OfficerTony Mauro said, “We've had numerous discussions with customers about the need for a unique launch strategy for the first substitutable generic of Advair Diskusthat increases affordability to all in our healthcare system. We trust that by launching WixelaInhub at a significantly discounted list price, we will demonstrate the savings that generics can deliver for patients through reduced out-of-pocket costs, as well as the U.S. healthcare system overall.”
In addition, Mylan will offer patient services to provide training and education about the treatment and device.
All the three strengths of WixelaInhub will be offered at a wholesale acquisition cost, 70% less than ADVAIR DISKUS and 67% less than GSK's authorized generic version